Search

Your search keyword '"Müller, Lothar"' showing total 769 results
Start Over Author "Müller, Lothar"

Refine your results

more »

more »

more »

more »
769 results on '"Müller, Lothar"'

151. Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study

Author

Pape, Ulrich-Frank, primary, Kasper, Stefan, additional, Meiler, Johannes, additional, Sinn, Marianne, additional, Vogel, Arndt, additional, Müller, Lothar, additional, Burkhard, Oswald, additional, Caca, Karel, additional, Heeg, Steffen, additional, Büchner-Steudel, Petra, additional, Rodriguez-Laval, Victor, additional, Kühl, Anja A, additional, Arsenic, Ruza, additional, Jansen, Holger, additional, Treasure, Peter, additional, and Utku, Nalân, additional

Published
2020
Full Text
View/download PDF

152. ABC5 – Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom, Lissabon, 16.11.2019 – Deutsche Expertengruppe kommentiert ABC5-Abstimmungsergebnisse

Author

Untch, Michael, additional, Würstlein, Rachel, additional, Lüftner, Diana, additional, Haidinger, Renate, additional, Fasching, Peter A., additional, Augustin, Doris, additional, Briest, Susanne, additional, Ettl, Johannes, additional, Förster, Frank, additional, Kurbacher, Christian M., additional, Lück, Hans-Joachim, additional, Marschner, Norbert, additional, Müller, Lothar, additional, Müller, Volkmar, additional, Radke, Isabel, additional, Ruckhäberle, Eugen, additional, Scheffen, Iris, additional, Schumacher-Wulf, Eva, additional, Schwoerer, Moritz, additional, Steinfeld-Birg, Dieter, additional, Ziegler-Löhr, Katja, additional, Thomssen, Christoph, additional, and Harbeck, Nadia, additional

Published
2020
Full Text
View/download PDF

153. ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019

Author

Untch, Michael, additional, Würstlein, Rachel, additional, Lüftner, Diana, additional, Haidinger, Renate, additional, Fasching, Peter A., additional, Augustin, Doris, additional, Briest, Susanne, additional, Ettl, Johannes, additional, Förster, Frank, additional, Kurbacher, Christian M., additional, Lück, Hans-Joachim, additional, Marschner, Norbert, additional, Müller, Lothar, additional, Müller, Volkmar, additional, Radke, Isabel, additional, Ruckhäberle, Eugen, additional, Scheffen, Iris, additional, Schumacher-Wulf, Eva, additional, Schwoerer, Moritz, additional, Steinfeld-Birg, Dieter, additional, Ziegler-Löhr, Katja, additional, Thomssen, Christoph, additional, and Harbeck, Nadia, additional

Published
2020
Full Text
View/download PDF

154. A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).

Author

Grünwald, Viktor, primary, Grüllich, Carsten, additional, Ivanyi, Philipp, additional, Wirth, Manfred, additional, Staib, Peter, additional, Schostak, Martin, additional, Dargatz, Philip, additional, Müller, Lothar, additional, Metz, Michael, additional, Bergmann, Lothar, additional, Steiner, Thomas, additional, Welslau, Manfred, additional, Lorch, Anja, additional, RAFIYAN, Mohammad-Reza, additional, Hellmis, Eva, additional, Hinke, Axel, additional, Meiler, Johannes, additional, Kretz, Thomas, additional, Loidl, Wolfgang C., additional, and Flörcken, Anne, additional

Published
2020
Full Text
View/download PDF

155. International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts

Author

Thomssen, Christoph, primary, Lüftner, Diana, additional, Untch, Michael, additional, Haidinger, Renate, additional, Würstlein, Rachel, additional, Harbeck, Nadia, additional, Augustin, Doris, additional, Briest, Susanne, additional, Ettl, Johannes, additional, Fasching, Peter A., additional, Förster, Frank, additional, Kurbacher, Christian M., additional, Lück, Hans-Joachim, additional, Marschner, Norbert, additional, Müller, Lothar, additional, Müller, Volkmar, additional, Perlova-Griff, Lidia, additional, Radke, Isabel, additional, Ruckhäberle, Eugen, additional, Scheffen, Iris, additional, Schumacher-Wulf, Eva, additional, Schwoerer, Moritz, additional, Steinfeld-Birg, Dieter, additional, and Ziegler-Löhr, Katja, additional

Published
2020
Full Text
View/download PDF

156. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).

Author

Modest, Dominik Paul, Karthaus, Meinolf, Fruehauf, Stefan, Graeven, Ullrich, Müller, Lothar, König, Alexander Otto, Fischer von Weikersthal, Ludwig, Caca, Karel, Kretzschmar, Albrecht, Goekkurt, Eray, Haas, Siegfried, Kurreck, Annika, Stahler, Arndt, Held, Swantje, Jarosch, Armin, Horst, David, Reinacher-Schick, Anke, Kasper, Stefan, Heinemann, Volker, and Stintzing, Sebastian

Published
2022
Full Text
View/download PDF

157. Zum Gedenken an Friedrich Christian Delius.

Author

Müller, Lothar

Subjects
GERMAN language, CULTURAL property, REMINISCENCE, RHETORIC, POETRY (Literary form), MEMORY
Abstract

Copyright of Jahrbuch der Deutschen Akademie für Sprache und Dichtung Darmstadt is the property of Wallstein Verlag and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022

158. Relevante Risiko- und Prognosefaktoren im Rahmen der Behandlung von Patienten mit fortgeschrittenem Nierenzellkarzinom - Daten aus dem RCC-Register

Author

Goebell, Peter J., Müller, Lothar, Staehler, Michael, Müller, Marianne, Kruggel, Lisa, Jänicke, Martina, and Marschner, Norbert

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Im Behandlungs-Algorithmus rücken aktuell Risiko- und Prognosefaktoren wieder in den Fokus und erlangen auch im Hinblick auf die Therapieempfehlungen in den Leitlinien hohe Relevanz. Vor diesem Hintergrund haben wir die derzeitigen Risikoklassifikationen (MSKCC und Heng) und weitere[zum vollständigen Text gelangen Sie über die oben angegebene URL], 45. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung

Published
2019

159. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Author

Michel, Christian, Burchert, Andreas, Hochhaus, Andreas, Saussele, Susanne, Neubauer, Andreas, Lauseker, Michael, Krause, Stefan W, Kolb, Hans-Jochem, Hossfeld, Dieter Kurt, Nerl, Christoph, Baerlocher, Gabriela M., Heim, Dominik, Brümmendorf, Tim H, Fabarius, Alice, Haferlach, Claudia, Schlegelberger, Brigitte, Balleisen, Leopold, Goebeler, Maria-Elisabeth, Hänel, Mathias, Ho, Anthony, Dengler, Jolanta, Falge, Christiane, Möhle, Robert, Kremers, Stephan, Kneba, Michael, Stegelmann, Frank, Köhne, Claus-Henning, Lindemann, Hans-Walter, Waller, Cornelius F, Spiekermann, Karsten, Berdel, Wolfgang E, Müller, Lothar, Edinger, Matthias, Mayer, Jiri, Beelen, Dietrich W, Bentz, Martin, Link, Hartmut, Hertenstein, Bernd, Fuchs, Roland, Wernli, Martin, Schlegel, Frank, Schlag, Rudolf, De Wit, Maike, Trümper, Lorenz, Hebart, Holger, Hahn, Markus, Thomalla, Jörg, Scheid, Christof, Schafhausen, Philippe, Verbeek, Walter, Eckart, Michael J, Gassmann, Winfried, Schenk, Michael, Brossart, Peter, Wündisch, Thomas, Geer, Thomas, Bildat, Stephan, Schäfer, Erhardt, Hasford, Joerg, Hehlmann, Rüdiger, and Pfirrmann, Markus

Subjects
hemic and lymphatic diseases, 610 Medicine & health, neoplasms
Abstract

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800mg (high-dose) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing the risk of losing deep molecular response is unknown. To gain insights into this clinically relevant question, we analyzed the outcome of imatinib dose reductions from 800mg to 400mg daily in the Chronic Myeloid Leukemia-Study IV. Of the 422 patients that were randomized to the 800mg arm, 68 reduced imatinib to 400mg after they had achieved at least a stable major molecular response. 61 of these 68 patients (90%) maintained major molecular remission on imatinib at 400mg. Five of the seven patients, who lost major molecular remission on the imatinib standard dose, regained major molecular remission while still on 400mg imatinib. Only two of 68 patients had to switch to more potent kinase inhibition to regain major molecular remission. Importantly, the lengths of the imatinib high-dose treatment intervals before and after achieving major molecular remission were associated with the probabilities of maintaining major molecular remission with the standard dose of imatinib. Together, data support that a deep molecular remission achieved with high-dose imatinib, can be safely maintained with standard dose in most patients. The study protocol was registered at ClinicalTrials.gov (NCT00055874).

Published
2019
Full Text
View/download PDF

163. Neuroendokrine Neoplasien im deutschen NET-Register

Author

Maasberg, Sebastian, Pape, Ulrich-Frank, Fottner, Christian, Goretzki, Peter E., Anlauf, Martin, Hörsch, Dieter, Cremer, Birgit, Schulte, Dominik M., Quietzsch, Detlef, Scheerer, Frank, Pöpperl, Gabriele, Pöppel, Thorsten, Begum, Nehara, Grohé, Christian, Rinke, Anja, Plöckinger, Ursula, Wiedenmann, Betram, Arnold, Rudolf, Neuhaus, Peter, Knapp, Wolfram H., Lehnert, Hendrick, Auernhammer, Christoph, Pavel, Marianne, Von Weikersthal, Ludwig Fischer, Schmidt, Bernd, Klein, Harald H., Essler, Markus, Neumann, Jörg-Dietrich, Hamann, Susanne, Steffens, Frank, Demtröder, Frank, Kröcher, Anke, Zoicas, Flavius, Lahner, Harald, Weber, Frank, Geiler, Michael, Raffel, Andreas, Krausch, Markus, Zimmermann, Patrick, Lerch, Markus M., Wirth, Thomas, Lang, Matthias, Ezziddin, Samer, Lammert, Frank, Bischoff, Marina, Altendorf-Hofmann, Annelore, Müller, Lothar, Hoffmeister, Albrecht, Klose, Silke, Musholt, Thomas J., Post, Stefan, Gertler, Ralf, Scheuerlein, Hubert, Bergmann, Tanja, Bisping, Guido, Knauerhase, Andreas, Rendenbach, Bernhard, Gro, Volker, Scheurlen, Michael, Mönig, Heiner, Kudlich, Theodor, Grabowski, Patricia, Watza, Felix, Scheidhauer, Klemens, and Möbius, Elke

Subjects
Gynecology, Neuroendocrine neoplasia, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Gastroenterology, medicine, Medizin, 030209 endocrinology & metabolism, business
Abstract

ZusammenfassungNeuroendokrine Neoplasien (NEN) umfassen eine seltene Tumorentität mit heterogener Biologie, Prognose und therapeutischen Optionen. In Zusammenhang mit der kürzlichen Publikation der ersten deutschen Leitlinie zur Diagnostik und Therapie von NEN erfolgte die Analyse der Kohorte des Deutschen NET-Registers der Deutschen Gesellschaft für Endokrinologie (DGE). Hierzu wurden 2686 Fälle extrahiert und ihre Patientencharakteristika wie Alter, Geschlecht, Primärtumorlokalisation, Grading und Staging dargestellt sowie das Gesamtüberleben berechnet. Zusätzlich wurden die systemischen Behandlungsstrategien in den beiden größten Untergruppen, NEN des Dünndarms und Pankreas, im Stadium der Metastasierung analysiert.Die Verteilung der Primärtumoren, die histopathologische Charakterisierung, das Tumorstadium sowie das Gesamtüberleben waren vergleichbar mit den Ergebnissen internationaler Registerstudien. Somatostatinanaloga (SSA) und die Peptid-Rezeptor-Radionuklid-Therapie (PRRT) waren die häufigsten systemischen Therapieverfahren bei Dünndarm-NEN. Hingegen wurde eine Chemotherapie – in Übereinstimmung mit der neuen Leitlinie – vor allem bei pankreatischen NEN eingesetzt und kam in der Erstlinie in ähnlicher Frequenz wie die SSA-Therapie bzw. in der Zweitlinie ähnlich häufig wie eine PRRT zum Einsatz. Prognostisch relevante Parameter waren die WHO-Klassifikation 2010 und das TNM-Staging.Die aktuelle Analyse des deutschen NET-Registers charakterisiert damit eine multizentrische, interdisziplinäre, deutschlandweite Kohorte von NEN-Patienten und beschreibt die angewendeten systemischen Therapieverfahren, das Gesamtüberleben und die prognostische Bedeutung der WHO-Klassifikation 2010 sowie des TNM-Stadiums.

Published
2018

164. Neuroendokrine Neoplasien im deutschen NET-Register

Author

Maasberg, Sebastian, additional, Pape, Ulrich-Frank, additional, Fottner, Christian, additional, Goretzki, Peter E., additional, Anlauf, Martin, additional, Hörsch, Dieter, additional, Cremer, Birgit, additional, Schulte, Dominik M., additional, Quietzsch, Detlef, additional, Scheerer, Frank, additional, Pöpperl, Gabriele, additional, Poeppel, Thorsten D., additional, Begum, Nehara, additional, Grohé, Christian, additional, Rinke, Anja, additional, Plöckinger, Ursula, additional, Wiedenmann, Betram, additional, Arnold, Rudolf, additional, Neuhaus, Peter, additional, Knapp, Wolfram H., additional, Lehnert, Hendrick, additional, Auernhammer, Christoph, additional, Pavel, Marianne, additional, Weikersthal, Ludwig Fischer von, additional, Schmidt, Bernd, additional, Klein, Harald H., additional, Essler, Markus, additional, Neumann, Jörg-Dietrich, additional, Hamann, Susanne, additional, Steffens, Frank, additional, Demtröder, Frank, additional, Kröcher, Anke, additional, Zoicas, Flavius, additional, Lahner, Harald, additional, Weber, Frank, additional, Geißler, Michael, additional, Raffel, Andreas, additional, Krausch, Markus, additional, Zimmermann, Patrick, additional, Lerch, Markus M., additional, Wirth, Thomas, additional, Lang, Matthias, additional, Ezziddin, Samer, additional, Lammert, Frank, additional, Bischoff, Marina, additional, Altendorf-Hofmann, Annelore, additional, Müller, Lothar, additional, Hoffmeister, Albrecht, additional, Klose, Silke, additional, Musholt, Thomas J., additional, Post, Stefan, additional, Gertler, Ralf, additional, Scheuerlein, Hubert, additional, Bergmann, Tanja, additional, Bisping, Guido, additional, Knauerhase, Andreas, additional, Rendenbach, Bernhard, additional, Groß, Volker, additional, Scheurlen, Michael, additional, Mönig, Heiner, additional, Kudlich, Theodor, additional, Grabowski, Patricia, additional, Watza, Felix, additional, Scheidhauer, Klemens, additional, and Möbius, Elke, additional

Published
2019
Full Text
View/download PDF

168. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Author

Griesinger, Frank, Sebastian, Martin, Brueckl, Wolfgang M., Hummel, Horst-Dieter, Jaeschke, Bastian, Kern, Jens, Wesseler, Claas, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Hipper, Annette, Groth, Annika, Weichert, Wilko, Dörfel, Steffen, Petersen, Volker, Schröder, Jan, Wilke, Jochen, Eberhardt, Wilfried E.E., Thomas, Michael, Ababei, Juliana, Alt, Jürgen, Ammon, Andreas, Anhuf, Jürgen, Azeh, Ivo, Bauer, Stefan, Behringer, Dirk, Berger, Winfried, Bernhardt, Christiane, Bertram, Mathias, Boesche, Michael, Bohnet, Sabine, Bruch, Harald-Robert, Brückl, Wolfgang, Burkhard-Meier, Ulrike, Christopoulos, Petros, Däßler, Klaus-Ulrich, de Wit, Maike, Dechow, Tobias, Depenbusch, Reinhard, Dietze, Lutz, Dommach, Markus, Dörfel, Steffen, Eberhardt, Wilfried, Elender, Corinna, Elsel, Wolfgang, Emde, Till-Oliver, Faehling, Martin, Fietz, Thomas, Fischer, Jürgen R., Flieger, Dimitri, Freidt, Anke, Freier, Werner, Frenzel, Christian, Fuchs, Florian, Fuchs, Roswitha, Gaska, Tobias, Gleiber, Wolfgang, Grah, Christian, Griesinger, Frank, Grohé, Christian, Groschek, Matthias, Güldenzoph, Björn, Günther, Andreas, Haas, Siegfried, Hackenthal, Matthias, Hagen, Volker, Hahn, Lars, Hannig Carla, Verena, Hansen, Richard, Harich, Hanns-Detlev, Heilmann, Monika, Heinrich, Kathrin, Hering-Schubert, Christiane, Heßling, Jörg, Hoffknecht, Petra, Hortig, Patricia, Hübner, Gerdt, Hummel, Horst-Dieter, Hutzschenreuter, Ulrich, Illmer, Thomas, Innig, Georg, Jaeschke, Bastian, Junghanß, Christian, Kaiser, Ulrich, Kamal, Haytham, Kambartel, Kato, Kern, Jens, Kimmich, Martin, Kingreen, Dorothea, Kirchen, Heinz, Klausmann, Martine, Klein, Ortwin, Kokowski, Konrad, Körber, Wolfgang, Kortsik, Cornelius, Koschel, Dirk, Krämer, Benoit, Krammer-Steiner, Beate, Laack, Eckart, Lamberti, Christof, Leistner, Rumo David, Losem, Christoph, Lück, Andreas, Maintz, Christoph, Martin, Kerstin, Medgenberg, Dirk, Metzenmacher, Martin, Meyer zum Büschenfelde, Christian, Meyn, Philipp, Moorahrend, Enno, Müller, Annette, Müller, Lothar, Neise, Michael, Nückel, Holger, Nusch, Arnd, Overbeck, Tobias, Pelz, Henning, Petersen, Volker, Peuser, Bettina, Plath, Margarete, Randerath, Winfried J., Rauh, Jacqueline, Reck, Martin, Reichert, Dietmar, Reinmuth, Niels, Reiser, Marcel, Repp, Roland, Reschke, Daniel, Rittmeyer, Achim, Rodemer, Yolanda, Sackmann, Sandra, Sadjadian, Parvis, Sandner, Reiner, Sauer, Annette, Schäfer, Harald, Schaudt, Christoph, Schlag, Rudolf, Schmidt, Burkhard, Schmitz, Stephan, Schröder, Jan, Schroeder, Michael, Schulze, Mathias, Schumann, Christian, Schütte, Wolfgang, Schwaiblmair, Martin, Schwindt Peter, Florian, Sebastian, Martin, Seese, Bernd, Seipelt, Gernot, Sorgenfrei, Thomas, Steiff, Johannes, Steiniger, Heike, Trarbach, Tanja, Tufman, Amanda, Uhlig, Jens, Vehling-Kaiser, Ursula, von der Heyde, Eyck, von Verschuer, Ulla, Waller, Cornelius, Wehler, Thomas, Weißenborn, Georg, Weißinger, Florian, Wermke, Martin, Wesseler, Claas, Wiegand, Jörg, Wilhelm, Stefan, Wilke, Jochen, Zahn, Mark-Oliver, Zaiss, Matthias, and Zeth, Matthias

Abstract

Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in real-world and to compare the outcome of “trial-ineligible” and “potentially trial-eligible” patients.

Published
2024
Full Text
View/download PDF

169. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC‐Registry.

Author

Staehler, Michael, Goebell, Peter J., Müller, Lothar, Emde, Till‐Oliver, Wetzel, Natalie, Kruggel, Lisa, Jänicke, Martina, and Marschner, Norbert

Subjects
RENAL cell carcinoma, TREATMENT effectiveness, PROGRESSION-free survival, PROTEIN-tyrosine kinases
Abstract

Non‐clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non‐clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first‐ and second‐line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC‐Registry), 99 patients with papillary mRCC treated with systemic first‐line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first‐line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression‐free survival from start of first‐line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow‐up, and 9% were alive at the end of the individual 3‐year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real‐world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. What's new? Over the past decade, the treatment landscape for locally advanced or metastatic renal cell carcinoma (mRCC) has dramatically changed. To date, however, guideline recommendations mainly address patients with clear cell mRCC, due to a lack of prospective Phase III evidence for the rarer, non‐clear cell mRCC subtypes. This is the first longitudinal, prospective cohort study evaluating treatment and survival of patients with papillary mRCC outside a prospective clinical trial setting. The presented real‐world data help bridge the evidence gap by revealing the frequent use and effectiveness of systemic clear cell mRCC therapy in papillary mRCC, with a seemingly inferior prognosis. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

170. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Author

Michel, Christian, primary, Burchert, Andreas, additional, Hochhaus, Andreas, additional, Saussele, Susanne, additional, Neubauer, Andreas, additional, Lauseker, Michael, additional, Krause, Stefan W., additional, Kolb, Hans-Jochem, additional, Hossfeld, Dieter Kurt, additional, Nerl, Christoph, additional, Baerlocher, Gabriela M., additional, Heim, Dominik, additional, Brümmendorf, Tim H, additional, Fabarius, Alice, additional, Haferlach, Claudia, additional, Schlegelberger, Brigitte, additional, Balleisen, Leopold, additional, Goebeler, Maria-Elisabeth, additional, Hänel, Mathias, additional, Ho, Anthony, additional, Dengler, Jolanta, additional, Falge, Christiane, additional, Möhle, Robert, additional, Kremers, Stephan, additional, Kneba, Michael, additional, Stegelmann, Frank, additional, Köhne, Claus-Henning, additional, Lindemann, Hans-Walter, additional, Waller, Cornelius F., additional, Spiekermann, Karsten, additional, Berdel, Wolfgang E., additional, Müller, Lothar, additional, Edinger, Matthias, additional, Mayer, Jiri, additional, Beelen, Dietrich W., additional, Bentz, Martin, additional, Link, Hartmut, additional, Hertenstein, Bernd, additional, Fuchs, Roland, additional, Wernli, Martin, additional, Schlegel, Frank, additional, Schlag, Rudolf, additional, de Wit, Maike, additional, Trümper, Lorenz, additional, Hebart, Holger, additional, Hahn, Markus, additional, Thomalla, Jörg, additional, Scheid, Christof, additional, Schafhausen, Philippe, additional, Verbeek, Walter, additional, Eckart, Michael J., additional, Gassmann, Winfried, additional, Schenk, Michael, additional, Brossart, Peter, additional, Wündisch, Thomas, additional, Geer, Thomas, additional, Bildat, Stephan, additional, Schäfer, Erhardt, additional, Hasford, Joerg, additional, Hehlmann, Rüdiger, additional, and Pfirrmann, Markus, additional

Published
2018
Full Text
View/download PDF

171. 4. Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom (ABC4), Lissabon, 04.11.2017

Author

Untch, Michael, additional, Würstlein, Rachel, additional, Marschner, Norbert, additional, Lüftner, Diana, additional, Augustin, Doris, additional, Briest, Susanne, additional, Ettl, Johannes, additional, Haidinger, Renate, additional, Müller, Lothar, additional, Müller, Volkmar, additional, Ruckhäberle, Eugen, additional, Harbeck, Nadia, additional, and Thomssen, Christoph, additional

Published
2018
Full Text
View/download PDF

172. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Author

Thomas, M., primary, Ponce-Aix, S., additional, Navarro, A., additional, Riera-Knorrenschild, J., additional, Schmidt, M., additional, Wiegert, E., additional, Kapp, K., additional, Wittig, B., additional, Mauri, C., additional, Dómine Gómez, M., additional, Kollmeier, J., additional, Sadjadian, P., additional, Fröhling, K -P, additional, Huber, R.M., additional, Wolf, M., additional, Pall, Georg, additional, Surmont, Veerle, additional, Bosquee, Léon, additional, Germonpré, Paul, additional, Brückl, Wolfgang, additional, Grah, Christina, additional, Herzmann, Christian, additional, Leistner, Rumo, additional, Meyer, Andreas, additional, Müller, Lothar, additional, Schmalz, Oliver, additional, Scholz, Christian, additional, Schröder, Michael, additional, Serke, Monika, additional, Wesseler, Claas, additional, Brandts, Christian, additional, Kopp, Hans-Georg, additional, Blau, Wolfgang, additional, Griesinger, Frank, additional, Campelo, Maria Rosario Garcia, additional, Garcia, Yolanda Garcia, additional, and Perez, José Manuel Trigo, additional

Published
2018
Full Text
View/download PDF

173. A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.

Author

Seufferlein, Thomas, primary, Lausser, Ludwig, additional, Stein, Alexander, additional, Prager, Gerald W., additional, Kasper, Stefan, additional, Niedermeier, Michael, additional, Müller, Lothar, additional, Kubicka, Stefan, additional, Koenig, Alexander, additional, Buechner-Steudel, Petra, additional, Wille, Kai, additional, Perkhofer, Lukas, additional, Hann, Alexander, additional, Berger, Andreas Wolfgang, additional, Arnold, Dirk, additional, Kestler, Hans, additional, and Ettrich, Thomas Jens, additional

Published
2018
Full Text
View/download PDF

174. ABC4 Consensus: Assessment by a German Group of Experts

Author

Harbeck, Nadia, primary, Lüftner, Diana, additional, Marschner, Norbert, additional, Untch, Michael, additional, Augustin, Doris, additional, Briest, Susanne, additional, Ettl, Johannes, additional, Haidinger, Renate, additional, Müller, Lothar, additional, Müller, Volkmar, additional, Ruckhäberle, Eugen, additional, Wuerstlein, Rachel, additional, and Thomssen, Christoph, additional

Published
2018
Full Text
View/download PDF

175. Wenn Venedig stirbt:Über den Ausverkauf unserer Städte

Author

Settis, Salvatore and Müller, Lothar

Abstract

Ein dringlicher Appell an uns alle: Wenn wir unsere Städte und unser kulturelles Erbe weiterhin einem so rücksichtslosen Profitstreben ausliefern, werden sie untergehen – und wir mit ihnen. Venedig mit seiner einzigartigen Architektur, Geschichte und geographischen Lage, aber auch Venedig als Ausbund der Kommerzialisierung dieser Einzigartigkeit nimmt Salvatore Settis, der zum kulturellen Gewissen Italiens geworden ist, als Ausgangspunkt für grundsätzliche Überlegungen: Gibt es so etwas wie die Seele einer Stadt? Und worin genau bestünde diese? Vielleicht in ihrer Geschichte, ihren Einwohnern, ihrer Eigentümlichkeit? Warum gehören Wolkenkratzer zu New York, aber nicht nach Venedig? Sollte man die Schönheit einer Stadt als »Weltkulturerbe« konservieren, oder brauchen Städte eine »kreative Zerstörung«? Wie steht es mit dem »Recht auf Stadt«? Wie mit den Rechten künftiger Generationen? Venedig – ein emblematisches Beispiel für die Zukunft unserer Städte.Salvatore Settis wurde in Rosarno/Kalabrien geboren. Der Archäologe und Kunsthistoriker leitete von 1994 bis 1999 das Getty Research Institute for the History of Art in Los Angeles. Danach lehrte er an der Scuola Normale Superiore in Pisa Klassische Archäologie. Von 1999 bis 2010 war er Direktor dieser Universität. Lothar Müller, geboren in Dortmund, Kultur- und Literaturwissenschaftler, ist Redakteur im Feuilleton der Süddeutschen Zeitung und Honorarprofessor an der Humboldt-Universität zu Berlin. Für seine feuilletonistische Arbeit wurde er unter anderem mit dem Alfred-Kerr-Preis ausgezeichnet. Un appello urgente rivolto a tutti noi: se continuiamo ad approfittare in maniera così sconsiderata del nostro patrimonio culturale, le città sprofonderanno – e noi con loro. Salvatore Settis – ormai coscienza culturale dell’Italia – parte dall’unicità di Venezia, con le sue architetture, la sua storia e la sua geografia, passando per la Venezia apice della commercializzazione, come punto di partenza per una riflessione di fondo: esiste l’“anima” di una città? E in cosa consiste esattamente? Consiste forse nella sua storia, nei suoi abitanti, nelle sue peculiarità? Perché i grattacieli appartengono a New York ma non a Venezia? Si deve conservare la bellezza come “patrimonio dell’umanità” o le città hanno piuttosto bisogno di una “distruzione creativa”? Si può parlare di un diritto alla città e cosa ne sarà dei diritti delle generazioni future? Venezia: un esempio emblematico per il futuro delle nostre città.Salvatore Settis é nato a Rosarno (Calabria). Archeologo e storico dell’arte, ha condotto dal 1994 al 1999 il Getty Research Institute per la Storia dell’arte a Los Angeles, poi dal 1999 al 2010 la Scuola Normale di Pisa, di cui è stato anche professore di Archeologia classica. Lothar Müller é nato a Dortmund. Esperto di Cultura e Letteratura, è redattore del Feuilleton della Süddeutschen Zeitung con sede a Berlino e professore onorario della Humboldt-Universität zu Berlin. Per il suo lavoro giornalistico è stato insignito del premio Alfred Kerr.The event, like all events at the ICI Berlin, is open to the public, free of charge. The audience is presumed to consent to a possible recording on the part of the ICI Berlin. If you would like to attend the event yet might require assistance, please contact Event Management. Salvatore Settis and Lothar Müller, Wenn Venedig stirbt: Über den Ausverkauf unserer Städte, discussion, ICI Berlin, 9 May 2016

Published
2016

176. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Lang, Alois, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, Van Laethem, Jean-Luc, Van Cutsem, Eric, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, RezaieKalantari, Hassan, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Ychou, Marc, Zawadi, Ayman, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, MatysiakBudnik, Tamara, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, GuenterDerigs, Hans, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Labianca, Roberto, Colucci, Giuseppe, Amadori, Dino, Mini, Enrico, Falcone, Alfredo, Boni, Corrado, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Corsi, Domenico Cristi, Salvagni, Stefania, Chiara, Silvana, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Tabernero, Josep, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Valera, Javier Sastre, ValladaresAyerbes, Manuel, FeliuBatlle, Jaime, Gil, Silvia, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, CireraNogueras, Luis, Merino, BernadoQueralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, PijaumePericay, Carlos, ConstenlaFigueiras, Manuel, Jordan, InmaculadaGuasch, GomeReina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, MarcuelloGaspar, Eugenio, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, GuillotMorales, Monica, LlanosMuñoz, Marta, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, HernandezBusquier, Isabel, Ruiz, Teresa Checa, LacastaMuñoa, Adelaida, Aliguer, MiquelNogue, Ortiz de Taranco, Amalia Velasco, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, GalanBrotons, Antonio, AlbiolRodriguez, Santiago, Martinez, Jose Ales, Ruiz, Liliana Canosa, CentellesRuiz, Margarita, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, and Samuel, Leslie

Published
2015
Full Text
View/download PDF

177. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach

Author

Schmalenberg, Harald, primary, Al-Batran, Salah-Eddin, additional, Pauligk, Claudia, additional, Zander, Thomas, additional, Reichart, Alexander, additional, Lindig, Udo, additional, Kleiß, Mathias, additional, Müller, Lothar, additional, Bolling, Claus, additional, Seufferlein, Thomas, additional, Reichardt, Peter, additional, Kullmann, Frank, additional, Eschenburg, Henning, additional, Schmittel, Alexander, additional, Egger, Matthias, additional, Block, Andreas, additional, and Goetze, Thorsten Oliver, additional

Published
2017
Full Text
View/download PDF

178. A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST).

Author

Schmalenberg, Harald, primary, Pauligk, Claudia, additional, Zander, Thomas, additional, Reichart, Alexander, additional, Lindig, Udo, additional, Kleiss, Mathias, additional, Müller, Lothar, additional, Bolling, Claus, additional, Seufferlein, Thomas, additional, Reichardt, Peter, additional, Kullmann, Frank, additional, Eschenburg, Henning, additional, Schmittel, Alexander, additional, Egger, Matthias, additional, Block, Andreas, additional, Al-Batran, Salah-Eddin, additional, and Goetze, Thorsten Oliver, additional

Published
2017
Full Text
View/download PDF

179. Association of microsatellite instability with distinct clinical and molecular characteristics in resected colon cancer: Analysis of a platform trial of the AIO colorectal study group—Colopredict Plus.

Author

Reinacher-Schick, Anke C., primary, Juette, Hendrik, additional, Noepel-Duennebacke, Stefanie, additional, Arnold, Dirk, additional, Basara, Nadezda, additional, Boehner, Hinrich, additional, Dahm, Thorsten, additional, Feder, Inke Sabine, additional, Hansen, Olaf, additional, Hiller, Wolfgang, additional, Leins, Alexander, additional, Müller, Lothar, additional, Ueberrueck, Torsten, additional, Teschendorf, Christian, additional, Trenn, Guido, additional, Verdoodt, Berlinda, additional, Zwingmann, Nadine, additional, Uhl, Waldemar, additional, and Tannapfel, Andrea, additional

Published
2017
Full Text
View/download PDF

183. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer : results of the PELICAN study

Author

Harbeck, Nadia, Saupe, Steffen, Jäger, Elke, Schmidt, Marcus, Kreienberg, Rolf, Müller, Lothar, Otremba, Burkhard, Waldenmaier, Dirk, Dorn, Julia, Warm, Mathias, Scholz, Michael, Untch, Michael, Wit, Maike de, Barinoff, Jana, Lück, Hans-Joachim, Harter, Philipp, Augustin, Doris, Harnett, Paul, Beckmann, Matthias Wilhelm, Batran, Salah-Eddin al, Harbeck, Nadia, Saupe, Steffen, Jäger, Elke, Schmidt, Marcus, Kreienberg, Rolf, Müller, Lothar, Otremba, Burkhard, Waldenmaier, Dirk, Dorn, Julia, Warm, Mathias, Scholz, Michael, Untch, Michael, Wit, Maike de, Barinoff, Jana, Lück, Hans-Joachim, Harter, Philipp, Augustin, Doris, Harnett, Paul, Beckmann, Matthias Wilhelm, and Batran, Salah-Eddin al

Abstract

Purpose: The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC). Methods: This randomized, phase III, open-label, multicenter trial enrolled first-line MBC patients who were ineligible for endocrine or trastuzumab therapy. Cumulative adjuvant anthracyclines of 360 mg/m2 doxorubicin or equivalent were allowed. Left ventricular ejection fraction of >50 % was required. Patients received PLD 50 mg/m2 every 28 days or capecitabine 1250 mg/m2 twice daily for 14 days every 21 days. The primary endpoint was time-to-disease progression (TTP). Results: 210 patients were randomized (n = 105, PLD and n = 105, capecitabine). Adjuvant anthracyclines were given to 37 % (PLD) and 36 % (capecitabine) of patients. No significant difference was observed in TTP [HR = 1.21 (95 % confidence interval, 0.838–1.750)]. Median TTP was 6.0 months for both PLD and capecitabine. Comparing patients with or without prior anthracyclines, no significant difference in TTP was observed in the PLD arm (log-rank P = 0.64). For PLD versus capecitabine, respectively, overall survival (median, 23.3 months vs. 26.8 months) and time-to-treatment failure (median, 4.6 months vs. 3.7 months) were not statistically significantly different. Compared to PLD, patients on capecitabine experienced more serious adverse events (P = 0.015) and more cardiac events among patients who had prior anthracycline exposure (18 vs. 8 %; P = 0.31). Conclusion: Both PLD and capecitabine are effective first-line agents for MBC.

Published
2016

188. ABC3 Consensus: Assessment by a German Group of Experts

Author

Thomssen, Christoph, primary, Augustin, Doris, additional, Ettl, Johannes, additional, Haidinger, Renate, additional, Lück, Hans-Joachim, additional, Lüftner, Diana, additional, Marmé, Frederik, additional, Marschner, Norbert, additional, Müller, Lothar, additional, Overkamp, Friedrich, additional, Ruckhäberle, Eugen, additional, Thill, Marc, additional, Untch, Michael, additional, Wuerstlein, Rachel, additional, and Harbeck, Nadia, additional

Published
2016
Full Text
View/download PDF

191. IGLV3-21 R110Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Author

Yosifov, Deyan Y., Robrecht, Sandra, Giza, Adam, Riecke, Armin, Schneider, Christof, Jebaraj, Billy, Jumaa, Hassan, Young, Marc, Müller, Lothar, Vehling-Kaiser, Ursula, Eckart, Michael J., Freier, Werner, Schöttker, Björn, Gaska, Tobias, Reiser, Marcel, Fink, Anna-Maria, Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael, Langerbeins, Petra, Stilgenbauer, Stephan, and Tausch, Eugen

Abstract

INTRODUCTION:IGLV3-21 R110is a point mutation that can confer the ability for autonomous signaling to B cell receptors (BCR) using light chains encoded by the allele IGLV3-21 ∗ 01or IGLV3-21 ∗ 04. Chronic lymphocytic leukemia (CLL) patients with IGLV3-21 R110have a shorter time to first treatment and shorter overall survival, independent of their IGHV mutational status. However, outcomes of CLL patients using IGLV3-21 R110have not been evaluated in clinical trials of BTK inhibitors.

Published
2023
Full Text
View/download PDF

195. Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Author

Langerbeins, Petra, primary, Bahlo, Jasmin, additional, Rhein, Christina, additional, Cramer, Paula, additional, Fink, Anna-Maria, additional, Pflug, Natali, additional, von Tresckow, Julia, additional, Stilgenbauer, Stephan, additional, Kreuzer, Karl-Anton, additional, Eckart, Michael J., additional, Vehling-Kaiser, Ursula, additional, Schlag, Rudolf, additional, Balser, Christina, additional, Müller, Lothar, additional, Wendtner, Clemens-Martin, additional, Fischer, Kirsten, additional, Eichhorst, Barbara, additional, and Hallek, Michael, additional

Published
2015
Full Text
View/download PDF

196. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group

Author

Goede, Valentin, primary, Busch, Raymonde, additional, Bahlo, Jasmin, additional, Chataline, Viktoria, additional, Kremers, Stephan, additional, Müller, Lothar, additional, Reschke, Daniel, additional, Schlag, Rudolf, additional, Schmidt, Burkhard, additional, Vehling-Kaiser, Ursula, additional, Wedding, Ulrich, additional, Stilgenbauer, Stefan, additional, and Hallek, Michael, additional

Published
2015
Full Text
View/download PDF

198. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial

Author

Pelzer, Uwe, primary, Opitz, Bernhard, additional, Deutschinoff, Gerd, additional, Stauch, Martina, additional, Reitzig, Peter C., additional, Hahnfeld, Sabine, additional, Müller, Lothar, additional, Grunewald, Martina, additional, Stieler, Jens M., additional, Sinn, Marianne, additional, Denecke, Timm, additional, Bischoff, Sven, additional, Oettle, Helmut, additional, Dörken, Bernd, additional, and Riess, Hanno, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results